Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : HONG KONG -- Ignore unavailable to you. Want to Upgrade?

To: Ron Bower who wrote (2306)	9/9/1998 1:31:00 PM
From: Tom	Respond to of 2951

Ron: Guangzhou Pharma is the one I've seen more frequently, but only because it's listed in Hong Kong. I have attempted to pull something from that sector, but am forever being distracted from it -- for some reason or another. My very first thought on regional pharmaceuticals was something to do with product integration, or the bilateral marketplace. There is what we consider traditional medicine, and there is traditional Chinese medicine. I think there might be some opportunity where the two co-operate. Now I recall why I've been distracted from the investment aspect. I get caught-up reading about traditional Oriental health care. Lately, however, I've been tempted to just tell them to take their Middle Kingdom smugness and shove it.... Whoops, sorry. Getting off topic. Additionally, the big boys are in the game, of course (Hafslund Nycomed, Squibb, et al.) I'll send along the latest on Guangzhou Pharma. Maybe you can do a little extrapolating.